Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Core Essence Orthopaedics names new chairman
From 1990-1997, Mr Moran served as president of Synthes Spine, a division of Synthes (USA) that designs, manufactures and distributes implants and instruments for spinal disorders. Mr Moran
From 1990-1997, Mr Moran served as president of Synthes Spine, a division of Synthes (USA) that designs, manufactures and distributes implants and instruments for spinal disorders. Mr Moran
This study involves the prospective collection of samples from well-characterized Parkinson’s patients combined with Arrayit’s new H25K microarray technology. The first experiments have enabled rapid and efficient sample
Dr Carter takes over from Robert Bertoldi, who was serving as interim CEO. Mr Bertoldi will continue in his WellGen board position and as president and CFO of
Gilead Sciences, a biopharmaceutical company, has reported that DAR-311, a Phase III clinical trial evaluating the company’s endothelin receptor antagonist darusentan for the treatment of resistant hypertension, met
Leading the $4 million bridge financing were The Aurora Funds, and S-Group Direct Investments, along with participation from other existing investors Innovation Ventures and several individuals. Ray Swanson,
SiDMAP’s new Japanese clients will use SiDMAP’s services to study the mechanisms of action and identify potential efficacy biomarkers for drugs designed to treat diseases such as diabetes,
Tekmira Pharmaceuticals, a biopharmaceutical company, has announced that one of the company’s collaborators, Alnylam Pharmaceuticals, has initiated a Phase I human clinical trial of ALN-VSP in the US.
CardioNet, a wireless medical technology company, and Biotel, a developer of medical devices and related software products, have entered into a binding definitive merger agreement, pursuant to which,
Biovista, a drug development services company, has reported that BVA-101, its drug targeting multiple sclerosis, has shown significant positive results in the myelin oligodendrocyte protein-induced experimental allergic encephalomyelitis
Osiris Therapeutics, a stem cell therapeutic company, has started treatment of the first patient in a Phase II clinical trial evaluating Prochymal for the treatment of heart attacks.